These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11732275)

  • 1. [The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials].
    Kwieciński H; Janik P; Jamrozik Z; Opuchlik A
    Neurol Neurochir Pol; 2001; 35(1 Suppl):101-6. PubMed ID: 11732275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
    Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
    J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis.
    Mazzini L; Testa D; Balzarini C; Mora G
    J Neurol; 1994 Feb; 241(4):223-7. PubMed ID: 8195821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes].
    Szczudlik A; Tomik B; Słowik A; Kasprzyk K
    Neurol Neurochir Pol; 1998; 32(4):821-9. PubMed ID: 9864711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis.
    Lange DJ; Murphy PL; Diamond B; Appel V; Lai EC; Younger DS; Appel SH
    Arch Neurol; 1998 Jan; 55(1):93-6. PubMed ID: 9443715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study.
    Galbussera A; Tremolizzo L; Brighina L; Testa D; Lovati R; Ferrarese C; Cavaletti G; Filippini G
    Neurol Sci; 2006 Jul; 27(3):190-3. PubMed ID: 16897634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
    LeWitt PA
    J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.
    Park SB; Vucic S; Cheah BC; Lin CS; Kirby A; Mann KP; Zoing MC; Winhammar J; Kiernan MC
    EBioMedicine; 2015 Dec; 2(12):1916-22. PubMed ID: 26844270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline and vitamin E in Alzheimer's disease.
    Adelman A
    J Fam Pract; 1997 Aug; 45(2):98-100. PubMed ID: 9267360
    [No Abstract]   [Full Text] [Related]  

  • 10. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
    Traynor BJ; Alexander M; Corr B; Frost E; Hardiman O
    J Neurol; 2003 Apr; 250(4):473-9. PubMed ID: 12700914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized sequential trial of creatine in amyotrophic lateral sclerosis.
    Groeneveld GJ; Veldink JH; van der Tweel I; Kalmijn S; Beijer C; de Visser M; Wokke JH; Franssen H; van den Berg LH
    Ann Neurol; 2003 Apr; 53(4):437-45. PubMed ID: 12666111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
    Piepers S; Veldink JH; de Jong SW; van der Tweel I; van der Pol WL; Uijtendaal EV; Schelhaas HJ; Scheffer H; de Visser M; de Jong JM; Wokke JH; Groeneveld GJ; van den Berg LH
    Ann Neurol; 2009 Aug; 66(2):227-34. PubMed ID: 19743466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
    Meininger V; Asselain B; Guillet P; Leigh PN; Ludolph A; Lacomblez L; Robberecht W;
    Neurology; 2006 Jan; 66(1):88-92. PubMed ID: 16401852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II/III randomized trial of TCH346 in patients with ALS.
    Miller R; Bradley W; Cudkowicz M; Hubble J; Meininger V; Mitsumoto H; Moore D; Pohlmann H; Sauer D; Silani V; Strong M; Swash M; Vernotica E;
    Neurology; 2007 Aug; 69(8):776-84. PubMed ID: 17709710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
    Shoulson I
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial.
    Chiò A; Borghero G; Calvo A; Capasso M; Caponnetto C; Corbo M; Giannini F; Logroscino G; Mandrioli J; Marcello N; Mazzini L; Moglia C; Monsurrò MR; Mora G; Patti F; Perini M; Pietrini V; Pisano F; Pupillo E; Sabatelli M; Salvi F; Silani V; Simone IL; Sorarù G; Tola MR; Volanti P; Beghi E;
    Neurology; 2010 Aug; 75(7):619-25. PubMed ID: 20702794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey.
    Clavelou P; Blanquet M; Peyrol F; Ouchchane L; Gerbaud L
    J Neurol Sci; 2013 Aug; 331(1-2):126-31. PubMed ID: 23809193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.